Gilead Sciences, Inc.GILD

Gilead Sciences reported net income of $2.02bn on revenue of $6.96bn for the first quarter of 2026, with diluted EPS of $1.61. Operating cash flow was $2.54bn, and the company spent $117m on property and equipment. The numbers confirm a business that generates enormous cash from its HIV franchise, led by Biktarvy, which saw sales rise 7% on higher demand and price.

The company is a biopharmaceutical giant focused on HIV, hepatitis, oncology, and cell therapy. HIV product sales alone hit $5bn in the quarter, up 10% year-over-year, driven by patient switches from older regimens. Trodelvy and Livdelzi also contributed to growth, while Veklury sales declined. Gilead retains commercialization rights for gamgertamig and pays Galapagos royalties of 20-23% on net sales.

Inventory stood at $1.91bn, up $52m from the prior period, reflecting normal supply chain dynamics. The company had $23.52bn in stockholders' equity on $56.28bn in total assets. Share count on a diluted basis was 1.25bn, meaning the buyback programme has been active but not dramatically shrinking the float.

The SEC EDGAR filing index shows multiple Form 4 and Form 144 filings in July 2026, indicating insider sales. While not unusual for a large cap, the volume and frequency are worth noting. The 10-Q was filed on May 7, 2026, and the earnings press release the same day.

What changed this quarter is the continued strength of HIV sales offsetting weakness in HCV and Veklury. The pipeline news is limited in the evidence, with no major approvals or failures reported. The insider selling pattern is the main new data point outside the financials.

What remains unproven is whether Gilead can sustain growth without a major new product. The reliance on HIV is a strength and a risk. The evidence does not include guidance for the next quarter, so the forward view is opaque.